PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue
On Dec 12, 2025, PMCB reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were PharmaCyte Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, PharmaCyte Biotech, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to PharmaCyte Biotech, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is PharmaCyte Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 16, 2026.
What are the forecasts for PharmaCyte Biotech, Inc. Common Stock's next earnings report?
Based on --
analysts, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q3 2026.